Difference between revisions of "Selumetinib (Koselugo)"
Jump to navigation
Jump to search
m |
m |
||
| Line 2: | Line 2: | ||
Inhibits the enzyme MAPK kinase (MEK), specifically the MEK1 and MEK2 subtypes of the enzyme. | Inhibits the enzyme MAPK kinase (MEK), specifically the MEK1 and MEK2 subtypes of the enzyme. | ||
| − | == | + | ==Preliminary data== |
| − | + | ''While this drug has been mentioned as "promising" numerous times, there are no phase II or phase III studies that have been published thus far with a clear beneficial effect.'' | |
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Chemotherapy]] | ||
| + | [[Category:Oral chemotherapy]] | ||
| − | |||
[[Category:Kinase inhibitors]] | [[Category:Kinase inhibitors]] | ||
[[Category:MEK inhibitors]] | [[Category:MEK inhibitors]] | ||
| − | [[Category: | + | [[Category:Investigational]] |
Revision as of 21:46, 25 November 2014
Mechanism of action
Inhibits the enzyme MAPK kinase (MEK), specifically the MEK1 and MEK2 subtypes of the enzyme.
Preliminary data
While this drug has been mentioned as "promising" numerous times, there are no phase II or phase III studies that have been published thus far with a clear beneficial effect.